Apyx Medical (APYX) Net Income towards Common Stockholders (2011 - 2026)

Apyx Medical (APYX) has reported Net Income towards Common Stockholders for 16 consecutive years, with -$3.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Income towards Common Stockholders rose 14.16% year-over-year to -$3.2 million; the trailing twelve-month figure through Jun 2026 stood at -$8.6 million (up 49.97% YoY), and the FY2025 full-year result was -$11.2 million, up 52.22% from the prior year.
• Net Income towards Common Stockholders fell to -$3.2 million in Q2 2026 per APYX's latest filing, from -$2.1 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$1.0 million in Q2 2023 and bottomed at -$9.6 million in Q4 2023.
• Historically, Net Income towards Common Stockholders has averaged -$4.6 million across 5 years, with a median of -$4.6 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders surged 81.3% in 2023, then sank 543.38% in 2024.
• Over 5 years, Net Income towards Common Stockholders stood at -$6.1 million in 2022, then slumped by 58.4% to -$9.6 million in 2023, then jumped by 51.83% to -$4.6 million in 2024, then soared by 71.93% to -$1.3 million in 2025, then tumbled by 149.65% to -$3.2 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$3.2 million, -$2.1 million, and -$1.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.